Results 161 to 170 of about 12,729,014 (274)

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Rapid Pre-Implementation Evaluation for Multi-Specialty Surgical Trials: Informing Context-Specific Adaptations. [PDF]

Ann Surg Open
Sasnal M, Giannitrapani KF, Langston AH, Doruk RN, Morris AM, Sox-Harris AH, Arya S.   +6 more
europepmc   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

Optimizing Heart Failure-Specific Disease Management Programs and Patient Care in Saudi Arabia: A Saudi Heart Association Position Statement. [PDF]

J Saudi Heart Assoc
Bakhsh A, Al Ayoubi F, Elshaer F, Albackr HB, Bogari HA, Jelaidan I, Raslan I, Al Ghalayini K, Alqaseer M, AlHabeeb W.   +9 more
europepmc   +1 more source

Awareness of the Black Triangle Scheme among healthcare professionals and consumers in Australia: A mixed‐methods study exploring reporting intentions and suggested improvements

British Journal of Clinical Pharmacology, EarlyView.
Aims The Black Triangle Scheme, introduced in 2018 in Australia, does not appear to have increased the quantity of adverse drug event (ADE) reports. This study evaluated healthcare professionals' (HCPs') and consumers' awareness of the scheme, its influence on intentions for future ADE reporting, and suggested improvements.
Eyob Alemayehu Gebreyohannes, Sieta T. de Vries, Mohammed Gebre Dedefo, Oliver Frank, Myra Thiessen, Lisa Kalisch Ellett, Christopher Thornton, Renly Lim   +7 more
wiley   +1 more source

Clinical Trials in Older Adults with Cardiovascular Multimorbidity: A Perspective on Pragmatic Trial Design. [PDF]

J Clin Med
Bonanad C, Sánchez-Ospina D, García-Blas S, Alonso-Salinas GL, Cepas-Guillén P, Raposeiras-Roubín S, Segura-Rodríguez D, Pérez-Cervera J, Ortiz-Cortés C, Corbí-Pascual M, Noguerón-García A, Rivadulla-Varela CM, Thiscal López-Lluva M, Vivas D, Galant-Parrado S, Jordá-Climent S, Izquierdo-Ortiz MJ.   +16 more
europepmc   +1 more source

Capacity building in medicines development and regulation in Africa—Overview on recent progress

British Journal of Clinical Pharmacology, EarlyView.
Aims Despite advances in health research and digital innovation, many African countries continue to face substantial resource constraints, fragmented capacity‐building efforts and a shortage of skilled professionals in medicines development and regulatory science.
Tirhani Maluleke, Emile Malan, Michael Reid, Patrick Bouic, Haylene Nell, Goonaseelan Pillai, Catriona Waitt, Bernd Rosenkranz   +7 more
wiley   +1 more source

Host-state biomarkers and clinical factors for stratification and optimization of cell therapy trials in chronic limb-threatening ischemia: A review. [PDF]

Regen Ther
Shimizu Y, Ntege EH, Matsuura N, Ishii T, Sunami H, Furukawa K, Nakaema M, Tokushige A, Inoue Y.   +8 more
europepmc   +1 more source

Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective

Biotechnology and Bioengineering, EarlyView.
Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga, Udisha Singh, Sachin Dattram Pawar   +2 more
wiley   +1 more source

Artificial Intelligence in Nuclear Medicine (2015-2025): Clinical Applications, Regulatory Governance, and Pharmacotherapeutic Implications. [PDF]

Cureus
Alpizar-Rojas M, Jaromirski-Segura H, Herrera-Jiménez LG, Castro-Gamboa JA, Mora-Jiménez J, Arguedas-Chacón S, Zavaleta-Monestel E.   +6 more
europepmc   +1 more source